Nolvadex 10 - Unique Pharma

Tamoxifen citrate, initially synthesized in 1962 by ICI Pharmaceuticals, became widely recognized as Nolvadex, a key SERM for breast cancer treatment. Approved by the FDA in 1977, it effectively blocks estrogen receptors in breast tissue, preventing cancer cell proliferation. In the bodybuilding community, tamoxifen is valued for its ability to reduce estrogenic effects like gynecomastia during anabolic steroid cycles. Additionally, it promotes testosterone recovery by stimulating luteinizing hormone (LH) and follicle-stimulating hormone (FSH), making it a vital component of post-cycle therapy .

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Nolvadex 10 by Unique Pharma, consult with your doctor or healthcare professional.